A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin's Lymphoma.

Trial Profile

A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2012

At a glance

  • Drugs Plitidepsin (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 10 Feb 2011 Actual end date (July 2010) added as reported by ClinicalTrials.gov.
    • 10 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Dec 2010 Updated results presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH-2010).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top